Funding Rounds
Synklino Series A (2022, $31M)
SynklinoDeveloper of a CMV-specific immunotoxin intended to eradicate cytomegalovirus infection.
Summary
Stage: Series A
Raised Amount: $31.90M
Raised Date: 2022-01-01
Stage: Series A
Raised Amount: $31.90M
Raised Date: 2022-01-01
